Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp

Astria Therapeutics (NASDAQ:ATXS) was upgraded by research analysts at Citizens Jmp to a “strong-buy” rating in a research note issued on Friday,Zacks.com reports.

ATXS has been the subject of several other reports. JMP Securities began coverage on Astria Therapeutics in a research note on Friday. They set an “outperform” rating and a $26.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Finally, Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $7.86 on Friday. The stock has a 50-day simple moving average of $8.93 and a 200 day simple moving average of $10.44. The stock has a market capitalization of $443.54 million, a P/E ratio of -3.76 and a beta of 0.70. Astria Therapeutics has a 52 week low of $7.16 and a 52 week high of $16.90.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Quest Partners LLC increased its position in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,798 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at approximately $107,000. PDT Partners LLC bought a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $140,000. Finally, SG Americas Securities LLC acquired a new stake in Astria Therapeutics during the third quarter worth approximately $155,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.